Luis Gerardo Rodriguez
Grup de recerca
- Mieloma, amiloidosi, macroglobulinèmia i altres gammapaties Accredited researcher (R3A)
Publicacions destacades
-
Complement as the enabler of carfilzomib-induced thrombotic microangiopathy
Autors:Referència: British Journal Of Haematology 2021. -
Nectin-2 expression on malignant plasma cells is associated with better response to TIGIT blockade in multiple myeloma
Autors:Referència: Clinical Cancer Research 2020. -
CAR T-Cells in Multiple Myeloma: State of the Art and Future Directions
Autors:Referència: Frontiers In Oncology 2020. -
Impact of severe acute kidney injury and chronic kidney disease on allogeneic hematopoietic cell transplant recipients: a retrospective single center analysis
Autors:Referència: Bone Marrow Transplantation 2020. -
Impact of intensifying primary antibiotic prophylaxis in at-home autologous stem cell transplantation program for lymphoma patients
Autors:Referència: Leukemia & Lymphoma 2020. -
A reproducible and safe at-home allogeneic haematopoietic cell transplant program: first experience in Central and Southern Europe
Autors:Referència: Bone Marrow Transplantation 2020. -
Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis.
Autors:Referència: Bone Marrow Transplantation 2019. -
Loss of the Immune Checkpoint CD85j/LILRB1 on Malignant Plasma Cells Contributes to Immune Escape in Multiple Myeloma.
Autors:Referència: Journal Of Immunology 2018. -
Bone marrow plasma cell infiltration in light chain amyloidosis: impact on organ involvement and outcome.
Autors:Referència: Amyloid-Journal Of Protein Folding Disorders 2018. -
Prognostic impact of immunoparesis at diagnosis and after treatment onset in patients with light-chain amyloidosis
Autors:Referència: Amyloid-Journal Of Protein Folding Disorders 2017.
Projectes destacats
-
Ensayo clínico fase II sobre el uso de un CART humanizado dirigido contra BCMA (ARI0002h) en pacientes con mieloma múltiple recaído/refractario a inhibidores del proteasoma, inmunomoduladores y anticuerpos anti-CD38
Finançador: Clínica Universitaria de Navarra; Complejo Hospitalario de Salamanca; Hospital Clínic de Barcelona; Institut d`Investigacions Biomèdiques August Pi i Sunyer (Participante)Durada: 01/01/2019 -
Biomedicine international training research programme for excellent clinician-scientists "BITRECS"
Investigador/a principal: Luis Gerardo Rodríguez LobatoFinançador: Institut d'investigació Biomèdiques August Pi i Sunyer (Sede o evento); La Caixa Foundation; Comisión Europea ; Institut d`Investigacions Biomèdiques August Pi i Sunyer (Participante); Biomedicine international training research programme for excellent clinician-scientists (BITRECS) (Programa financiador competitivo)Durada: 01/09/2019 - 01/08/2022 -
Improving CAR T cell immunotherapy through immune checkpoint inhibition to achieve a sustained response in patients with multiple myeloma.
Investigador/a principal: David Fernando Moreno FajardoFinançador: Institut d`Investigacions Biomèdiques August Pi i Sunyer (Sede o evento)Durada: 01/01/2019 - 01/01/2020